Radiotherapy & Oncology
Volume 93, Issue 2 , Pages 234-240 , November 2009

Carbon-11 acetate PET/CT based dose escalated IMRT in prostate cancer

  • Jan Seppälä

      Affiliations

    • Department of Oncology and Radiotherapy, Turku University Hospital, Turku, Finland
    • Corresponding Author InformationCorresponding author. Address: Dept of Radiotherapy (821), Turku University Hospital, P.O. Box 52, 20521 Turku, Finland.
    • ,
  • Marko Seppänen

      Affiliations

    • Turku PET Centre, Turku University Hospital, Turku, Finland
    • ,
  • Eveliina Arponen

      Affiliations

    • Turku PET Centre, Turku University Hospital, Turku, Finland
    • ,
  • Paula Lindholm

      Affiliations

    • Department of Oncology and Radiotherapy, Turku University Hospital, Turku, Finland
    • ,
  • Heikki Minn

      Affiliations

    • Department of Oncology and Radiotherapy, Turku University Hospital, Turku, Finland
    • Turku PET Centre, Turku University Hospital, Turku, Finland

Received 27 April 2009 ,Revised 31 July 2009 ,Accepted 4 August 2009.

References 

  1. Kupelian PA, Ciezki J, Reddy CA, Klein EA, Mahadevan A. Effect of increasing radiation doses on local and distant failures in patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;71:16–22
  2. Zelefsky MJ, Yamada Y, Fuks Z, et al. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys. 2008;71:1028–1033
  3. Eade TN, Hanlon AL, Horwitz EM, et al. What dose of external-beam radiation is high enough for prostate cancer?. Int J Radiat Oncol Biol Phys. 2007;68:682–689
  4. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:67–74
  5. Zelefsky MJ, Levin EJ, Hunt M, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:1124–1129
  6. van Lin EN, Fütterer JJ, Heijmink SW, et al. IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. Int J Radiat Oncol Biol Phys. 2006;65:291–303
  7. Fonteyne V, Villeirs G, Speleers B, et al. Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion. Int J Radiat Oncol Biol Phys. 2008;72:799–807
  8. Lian J, Xing L, Hunjan S, et al. Mapping of the prostate in endorectal coil-based MRI/MRSI and CT: a deformable registration and validation study. Med Phys. 2004;31:3087–3094
  9. Oyama N, Akino H, Kanamaru H, et al. 11C-acetate PET imaging of prostate cancer. J Nucl Med. 2002;43:181–186
  10. Morris MJ, Scher HI. (11)C-acetate PET imaging in prostate cancer. Eur J Nucl Med Mol Imaging. 2007;34:181–184
  11. Vees H, Buchegger F, Albrecht S, et al. 18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy. BJU Int. 2007;99:1415–1420
  12. Yamaguchi T, Lee J, Uemura H, et al. Prostate cancer: a comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy. Eur J Nucl Med Mol Imaging. 2005;32:742–748
  13. Hara T, Bansal A, DeGrado TR. Effect of hypoxia on the uptake of [methyl-3H]choline, [1–14C] acetate and [18F]FDG in cultured prostate cancer cells. Nucl Med Biol. 2006;33:977–984
  14. Oyama N, Miller TR, Dehdashti F, et al. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med. 2003;44:549–555
  15. Kato T, Tsukamoto E, Kuge Y, et al. Accumulation of [11C]acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer. Eur J Nucl Med Mol Imaging. 2002;29:1492–1495
  16. Schiepers C, Hoh CK, Nuyts J, et al. 1–11C-acetate kinetics of prostate cancer. J Nucl Med. 2008;49:206–215
  17. Wachter S, Tomek S, Kurtaran A, et al. 11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer. J Clin Oncol. 2006;24:2513–2519
  18. Ciernik IF, Brown DW, Schmid D, et al. 3D-segmentation of the 18F-choline PET signal for target volume definition in radiation therapy of the prostate. Technol Cancer Res Treat. 2007;6:23–30
  19. Pike VW, Eakins MN, Allan RM, Selwyn AP. Preparation of [1–11C]acetate – an agent for the study of myocardial metabolism by positron emission tomography. Int J Appl Radiat Isot. 1982;33:505–512
  20. Lyman JT. Complication probability as assessed from dose–volume histograms. Radiat Res. 1985;104:S13–S19
  21. Kutcher GJ, Burman C, Brewster L, Goitein M, Mohan R. Histogram reduction method for calculating complication probabilities for three-dimensional treatment planning evaluations. Int J Radiat Oncol Biol Phys. 1991;21:137–146
  22. Söhn M, Yan D, Liang J, et al. Incidence of late rectal bleeding in high-dose conformal radiotherapy of prostate cancer using equivalent uniform dose-based and dose–volume-based normal tissue complication probability models. Int J Radiat Oncol Biol Phys. 2007;67:1066–1073
  23. Marks LB, Carroll PR, Dugan TC, Anscher MS. The response of the urinary bladder, urethra, and ureter to radiation and chemotherapy. Int J Radiat Oncol Biol Phys. 1995;31:1257–1280
  24. Brenner DJ. Fractionation and late rectal toxicity. Int J Radiat Oncol Biol Phys. 2004;60:1013–1015
  25. Zaider M, Minerbo GN. Tumour control probability: a formulation applicable to any temporal protocol of dose delivery. Phys Med Biol. 2000;45:279–293
  26. Stavreva NA, Warkentin B, Stavrev PV, Fallone BG. Investigating the effect of clonogen resensitization on the tumor response to fractionated external radiotherapy. Med Phys. 2005 Mar;32:720–725
  27. Niemierko A. Reporting and analyzing dose distributions: a concept of equivalent uniform dose. Med Phys. 1997;24:103–110
  28. Wang JZ, Guerrero M, Li XA. How low is the alpha/beta ratio for prostate cancer?. Int J Radiat Oncol Biol Phys. 2003;55:194–203
  29. Ågren A, Brahme A, Turesson I. Optimization of uncomplicated control for head and neck tumors. Int J Radiat Oncol Biol Phys. 1990;19:1077–1085
  30. Dearnaley DP, Hall E, Lawrence D, et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer. 2005;92:488–498
  31. Cellini N, Morganti AG, Mattiucci GC, et al. Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. Int J Radiat Oncol Biol Phys. 2002;53:595–599
  32. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med. 2007;48:932–945
  33. Chen ME, Johnston DA, Tang K, Babaian RJ, Troncoso P. Detailed mapping of prostate carcinoma foci: biopsy strategy implications. Cancer. 2000;89:1800–1809
  34. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 1999;43:1095–1101
  35. Fowler J, Chappell R, Ritter M. Is alpha/beta for prostate tumors really low?. Int J Radiat Oncol Biol Phys. 2001;50:1021–1031
  36. King CR, Mayo CS. Is the prostate α/β ratio of 1.5 from Brenner and Hall a modeling artifact?. Int J Radiat Oncol Biol Phys. 2000;47:536–538
  37. Nutting CM, Corbishley CM, Sanchez-Nieto B, et al. Potential improvements in the therapeutic ratio of prostate cancer irradiation: dose escalation of pathologically identified tumour nodules using intensity modulated radiotherapy. Br J Radiol. 2002;75:151–161
  38. Speight JL, Roach M. Advances in the treatment of localized prostate cancer: the role of anatomic and functional imaging in men managed with radiotherapy. J Clin Oncol. 2007;25:987–995

PII: S0167-8140(09)00452-6

doi: 10.1016/j.radonc.2009.08.010

Radiotherapy & Oncology
Volume 93, Issue 2 , Pages 234-240 , November 2009

Article Tools

* Image Usage & Resolution